VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION

Ceklic, Lala; Munk, Marion; Wolf-Schnurrbusch, Ute; Gekkieva, Margarita; Wolf, Sebastian (2016). VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION. Retina - the journal of retinal and vitreous diseases, 37(4), pp. 687-693. Lippincott, Williams & Wilkins 10.1097/IAE.0000000000001236

[img]
Preview
Text
VISUAL_ACUITY_OUTCOMES_OF_RANIBIZUMAB_TREATMENT_IN.97356.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (163kB) | Preview

PURPOSE To investigate visual and morphological outcome in eyes with MRS and choroidal neovascularization (CNV) secondary to pathologic myopia treated with intravitreal (IVT) ranibizumab. METHODS Post hoc analysis of the patients included in the RADIANCE trial (n = 277) was performed to evaluate the impact of MRS on the functional outcome in patients with myopic choroidal neovascularization (mCNV) undergoing intravitreal ranibizumab injections. RESULTS Prevalence of MRS in pathologic myopia population is 6%. Respective patients were generally older than patients without MRS. Study eyes with MRS at baseline (BL) showed an initially poor treatment response after 3 months (mean change in best corrected visual acuity (BCVA) was 2.8 ± 12.4 letters, P = 0.009). After 12 months of treatment however, the mean change in BCVA was 7.1 ± 14.5 early treatment diabetic retinopathy study (ETDRS) letters (P = 0.025). Patients with MRS at baseline received more intravitreal injections than the other RADIANCE patients without MRS (MRS, n = 15 eyes: 5.8 ± 2.1 vs. RADIANCE non-MRS [n = 207 eyes]: 4.0 ± 2.9; P = 0.0001). CONCLUSION Improvement of visual acuity is delayed and reduced after 3 months intravitreal ranibizumab in eyes with MRS and myopic choroidal neovascularization compared to eyes without MRS. More ranibizumab injections are needed in eyes with MRS to gain comparable BCVA at Month 12.This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Munk, Marion; Wolf-Schnurrbusch, Ute and Wolf, Sebastian

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0275-004X

Publisher:

Lippincott, Williams & Wilkins

Language:

English

Submitter:

Sebastian Wolf

Date Deposited:

29 Aug 2016 10:40

Last Modified:

02 Apr 2017 02:12

Publisher DOI:

10.1097/IAE.0000000000001236

PubMed ID:

27533774

BORIS DOI:

10.7892/boris.86156

URI:

https://boris.unibe.ch/id/eprint/86156

Actions (login required)

Edit item Edit item
Provide Feedback